Strategic Partnerships Vizgen's merger with Ultivue and recent collaborations with Hamamatsu, along with backing from investors, create a multi-product spatial multi-omics ecosystem that enables co-sell and bundled solutions to academic labs, CROs, and translational medicine programs.

Product Expansion The global rollout of MERFISH 2.0 and development of the Cell Atlas platform open opportunities to cross-sell assays, in situ platforms, and data services to researchers pursuing single-cell spatial genomics and volumetric tissue mapping.

Financial Strength A recent funding round and a solid revenue base underscore Vizgen’s financial resilience, enabling larger deployments, multi-site deals, and long-term service contracts with leading universities and pharma partners.

Market Leadership As a leading private player in spatial biology, Vizgen’s high-precision MERFISH technology and integrated platform offer a compelling differentiator in a rapidly expanding market.

Customer Expansion There are broad sales opportunities across foundational biology, translational and clinical research, pathology workflows, and imaging analytics, with potential bundles including MoxiePlex integrations, InSituPlex assays, and STARVUE AI to address end-to-end spatial biomarker programs.